FOUNDATION**ONE**®CDx

PATIENT	**TUMOR TYPE**		**REPORT DATE**
Chou, Kung Po	Pancreas ductal adenocarcinoma		07 Apr 2023
	COUNTRY CODE		**ORDERED TEST #**
	TW		ORD-1600374-01

ABOUT THE TEST FoundationOne®CDx is a next-generation sequencing (NGS) based assay that identifies genomic findings within hundreds of cancer-related genes.

PATIENT
DISEASE Pancreas ductal adenocarcinoma
NAME Chou, Kung Po
DATE OF BIRTH 03 July 1972
SEX Male
MEDICAL RECORD # 47951020

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN SITE Pancreas
SPECIMEN ID S111-71014F (PF23031)
SPECIMEN TYPE Slide Deck
DATE OF COLLECTION 19 July 2022
SPECIMEN RECEIVED 31 March 2023

Biomarker Findings
Microsatellite status - MS-Stable
Tumor Mutational Burden - 4 Muts/Mb

Genomic Findings
For a complete list of the genes assayed, please refer to the Appendix.

BRCA1 splice site 5332+1G>A
KRAS Q61H
MTAP loss
CDKN2A/B CDKN2B loss, CDKN2A loss
TP53 C275W

1 Disease relevant genes with no reportable alterations: *BRCA2*

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: Olaparib (p. 9), Rucaparib (p. 10)

- Variants that may inform **nontargeted treatment approaches** (e.g., chemotherapy) in this tumor type: *BRCA1* splice site 5332+1G>A (p. 4)

- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 12)

- Variants in select cancer susceptibility genes to consider for possible **follow-up germline testing** in the appropriate clinical context: *BRCA1* splice site 5332+1G>A (p. 4)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS	
Microsatellite status - MS-Stable	No therapies or clinical trials. See Biomarker Findings section	
Tumor Mutational Burden - 4 Muts/Mb	No therapies or clinical trials. See Biomarker Findings section	

GENOMIC FINDINGS	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
BRCA1 - splice site 5332+1G>A	Olaparib [2A]	Rucaparib [2A]
		Niraparib
		Talazoparib
10 Trials see p. 12		
KRAS - Q61H	none	none
3 Trials see p. 14		
MTAP - loss	none	none
3 Trials see p. 15		

☐ *NCCN category*

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

COUNTRY CODE
TW

REPORT DATE
07 Apr 2023

ORDERED TEST #
ORD-1600374-01

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING IN SELECT CANCER SUSCEPTIBILITY GENES

Findings below have been previously reported as pathogenic germline in the ClinVar genomic database and were detected at an allele frequency of >10%. See appendix for details.

BRCA1 - splice site 5332+1G>A .... p. 4

This report does not indicate whether variants listed above are germline or somatic in this patient. In the appropriate clinical context, follow-up germline testing would be needed to determine whether a finding is germline or somatic.

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

CDKN2A/B - CDKN2B loss, CDKN2A loss .... p. 7   **TP53 -** C275W .... p. 8

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the agents listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and exhaustive. Neither the therapeutic agents nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies.

Therapies contained in this report may have been approved by the US FDA.

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

PAGE 2 OF 23

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

BIOMARKER FINDINGS

BIOMARKER
Microsatellite status

RESULT
MS-Stable

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —
On the basis of clinical evidence, MSS tumors are significantly less likely than MSI-H tumors to respond to anti-PD-1 immune checkpoint inhibitors[1-3], including approved therapies nivolumab and pembrolizumab[4]. In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI-H and experienced a significantly higher ORR compared with non-MSI-H cases (70% vs. 12%, p=0.001)[5].

FREQUENCY & PROGNOSIS
MSI is rare in pancreatic carcinoma, reported in less than 1% of samples (n=>1,000)[6-10]. The prognostic significance of MSI in pancreatic cancer is unknown (PubMed, Aug 2022).

FINDING SUMMARY
Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor[11]. Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2[11-13]. This sample is microsatellite-stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers[14-16]. MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins[11,13,15-16].

BIOMARKER
Tumor Mutational Burden

RESULT
4 Muts/Mb

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —
On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[17-19], anti-PD-1 therapies[17-20], and combination nivolumab and ipilimumab[21-26]. In multiple pan-tumor studies, increased tissue tumor mutational burden (TMB) was associated with sensitivity to immune checkpoint inhibitors[17-20,27-31]. In the KEYNOTE 158 trial of pembrolizumab monotherapy for patients with solid tumors, significant improvement in ORR was observed for patients with TMB ≥10 Muts/Mb (as measured by this assay) compared with those with TMB <10 Muts/Mb in a large cohort that included multiple tumor types[27]; similar findings were observed in the KEYNOTE 028 and 012 trials[20]. At the same TMB cutpoint, retrospective analysis of patients with solid tumors treated with any checkpoint inhibitor identified that tissue TMB scores ≥ 10 Muts/Mb were associated with prolonged time to treatment failure compared with scores <10 muts/Mb (HR=0.68)[31]. For patients with solid tumors treated with nivolumab plus ipilimumab in the CheckMate 848 trial, improved responses were observed in patients with a tissue TMB ≥ 10 Muts/Mb independent of blood TMB at any cutpoint in matched samples[32]. However, support for higher TMB thresholds and efficacy was observed in the prospective Phase 2 MyPathway trial of atezolizumab for patients with pan-solid tumors, where improved ORR and DCR was seen in patients with TMB ≥ 16 Muts/Mb than those with TMB ≥ 10 and <16 Muts/Mb[30]. Similarly, analyses across several solid tumor types reported that patients with higher TMB (defined as ≥16-20 Muts/Mb) achieved greater clinical benefit from PD-1 or PD-L1-targeting monotherapy compared with patients with higher TMB treated with chemotherapy[33] or those with lower TMB treated with PD-1 or PD-L1-targeting agents[18].

FREQUENCY & PROGNOSIS
Pancreatic carcinomas, including ductal and acinar subtypes, have been reported to harbor a median TMB of 2-3 mutations per megabase (muts/Mb), and 0-2% of cases have high TMB (>20 muts/Mb)[34]; TMB has not been assessed in pancreatic mucinous neoplasms (PubMed, Oct 2022). A study of patients with pancreatic ductal adenocarcinoma harboring mismatch repair gene mutations reported improved prognosis for patients with high TMB measured in tissue samples (defined as >50 mutations; survival 69-314 months) compared to those with lower TMB (average of 5.7 mutations; 10-42 months)[35].

FINDING SUMMARY
Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[36-37] and cigarette smoke in lung cancer[38-39], treatment with temozolomide-based chemotherapy in glioma[40-41], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[42-46], and microsatellite instability (MSI)[42,45-46]. This sample harbors a TMB level associated with lower rates of clinical benefit from treatment with PD-1- or PD-L1-targeting immune checkpoint inhibitors compared with patients with tumors harboring higher TMB levels, based on several studies in multiple solid tumor types[18-19,27].

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

PAGE 3 of 23

FOUNDATION**ONE**®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

GENOMIC FINDINGS

GENE
BRCA1

ALTERATION
splice site 5332+1G>A

HGVS VARIANT
NM_007294.3: c.5332+1G>A (p.?)

VARIANT CHROMOSOMAL POSITION
chr17:41203079

VARIANT ALLELE FREQUENCY (% VAF)
61.7%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Alterations that inactivate BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors[47-64] or ATR inhibitors[65-67]. Clinical responses to PARP inhibitors have been reported for patients with either germline or somatic BRCA1/2 mutations[48,53,56,63-64] and for patients with platinum-resistant or -refractory disease[47,52,59,62]. A randomized Phase 2 trial evaluating cisplatin and gemcitabine with or without veliparib in 50 patients with advanced pancreatic ductal adenocarcinomas (PDAC) harboring germline BRCA1/2 or PALB2 (gBRCA/PALB2+) mutations reported that the addition of the PARP inhibitor veliparib to chemotherapy did not significantly improve median PFS (10.1 vs. 9.7 months) or median OS (15.5 vs. 16.4 months) relative to chemotherapy alone[68]. In a Phase 1 trial of monotherapy treatment with the ATR inhibitor BAY1895344, 2 patients with deleterious BRCA1 alterations and platinum-refractory ovarian carcinoma experienced a PR or prolonged SD[65]. In other Phase 1 trials of combination approaches, a patient with BRCA1-mutated ovarian carcinoma experienced prolonged SD from the ATR inhibitor berzosertib combined with topotecan[66]; another patient with platinum- and PARP-inhibitory refractory ovarian cancer and an inactivating germline BRCA1 mutation experienced a PR from berzosertib plus carboplatin[69]; and a third patient with BRCA1-mutated triple-negative breast cancer (TNBC) experienced a PR to the ATR inhibitor

ceralasertib combined with olaparib[70]. Preclinical studies of BRCA1/2 inactivation in T-cell acute lymphoblastic leukemia (T-ALL)[71], ovarian carcinoma[72], and TNBC[73] showing reduced cell viability and increased DNA damage during ATR treatment further support the sensitivity of BRCA1-deficient cells to ATR inhibitors. The WEE1 inhibitor adavosertib has been evaluated as a monotherapy and in combination with PARP-inhibitor, olaparib. In a Phase 2 study for patients with PARP-resistant ovarian cancer, the combination of olaparib and adavosertib elicited improved clinical benefit (ORR: 29%; DCR: 89%) compared to adavosertib alone (ORR: 23%; DCR: 63%); however, in the BRCA-mutated cohort, no significant difference in clinical benefit was observed between the combination (ORR: 19%) and monotherapy (ORR: 20%) treatments[74]. In a Phase 1 monotherapy trial of adavosertib that included 9 patients with BRCA1/2-mutated solid tumors, 2 patients with BRCA1-mutated cancers (1 with ovarian serous carcinoma and 1 with oral squamous cell carcinoma) achieved PRs, and a third patient with ovarian serous carcinoma harboring mutations in BRCA1 and TP53 experienced 14% tumor shrinkage prior to disease progression[75]. The Phase 1/2 PETRA study of PARP1 inhibitor AZD5305 observed a 25% (10/40) ORR (10 PR), for patients with BRCA1/2, PALB2, or RAD51C-mutated breast, ovarian, pancreatic, or prostate cancer, including 5 patients with prior PARP inhibitor treatment[76].

— Nontargeted Approaches —

Inactivation of BRCA1 may also predict sensitivity to the DNA-damaging agents trabectedin and lurbinectedin[77-86]. Patients with pancreatic cancer and BRCA1/2 or PALB2 mutations may benefit from FOLFIRINOX, or the combination of cisplatin and gemcitabine (NCCN Pancreatic Adenocarcinoma Guidelines, v2.2022)[68,87-90].

FREQUENCY & PROGNOSIS
In pancreatic carcinoma datasets, BRCA1 mutation and loss has been respectively reported in 1% and 0-1% of cases[91-92]. Reduced expression of BRCA1 at the mRNA and protein levels has been observed in

pancreatic adenocarcinoma, with low or no expression of BRCA1 protein in 50% of cases[93]. Although most cases of pancreatic cancer are sporadic, germline mutations in BRCA1 and BRCA2 have been linked to an increased risk of pancreatic cancer, particularly in families of Ashkenazi Jewish descent[94-98]. Reduced expression of BRCA1 at the mRNA and protein levels has been observed in pancreatic adenocarcinoma, with low or no expression of BRCA1 protein in 50% of cases; reduced or absent BRCA1 expression was found to be associated with poorer 1-year overall survival[93].

FINDING SUMMARY
The protein encoded by BRCA1 is involved in the maintenance of genomic stability, including DNA repair, cell cycle checkpoint, and chromosome segregation[99]. Alterations such as seen here may disrupt BRCA1 function or expression[100-102].

POTENTIAL GERMLINE IMPLICATIONS
One or more of the BRCA1 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with hereditary breast and ovarian cancer syndrome (ClinVar, Sep 2022)[103]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Inactivating germline mutations in BRCA1 or BRCA2 are associated with autosomal dominant hereditary breast and ovarian cancer[104-105], and the lifetime risk of breast and ovarian cancer in BRCA1/2 mutation carriers has been estimated to be as high as 87% and 44%, respectively[106]. Elevated risk for other cancer types, including gastric, pancreatic, prostate, and colorectal, has also been identified, with an increase in risk ranging from 20 to 60%[95]. The estimated prevalence of deleterious germline BRCA1/2 mutations in the general population is between 1:400 and 1:800, with an approximately 10-fold higher prevalence in the Ashkenazi Jewish population[106-112]. In the appropriate clinical context, germline testing of BRCA1 is recommended.

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

GENOMIC FINDINGS

ORDERED TEST #   ORD-1600374-01

GENE
KRAS

ALTERATION
Q61H

HGVS VARIANT
NM_004985.3: c.183A>T (p.Q61H)

VARIANT CHROMOSOMAL POSITION
chr12:25380275

VARIANT ALLELE FREQUENCY (% VAF)
11.1%

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —
Preclinical evidence suggests that KRAS activation may predict sensitivity to MEK inhibitors, such as trametinib, binimetinib, cobimetinib, and selumetinib[113-118]. For patients with pancreatic cancer, MEK inhibitor combinations are under investigation. A Phase 2 study of trametinib with pembrolizumab versus gemcitabine after stereotactic body radiotherapy (SBRT) reported increased median OS (mOS, 14.9 months vs. 12.8 months, HR=0.69) benefit for patients with KRAS-mutated, PD-L1 positive disease[119]. Combination MEK/autophagy inhibitors are also under investigation based on preclinical evidence of increased autophagy downstream of KRAS-mutated pancreatic tumors[120-121]. A heavily pretreated patient with pancreatic cancer treated with trametinib plus hydroxychloroquine

experienced a PR[120]. A Phase 2 study of the reoviral agent pelareorep with gemcitabine for patients with pancreatic cancer reported 1 PR, 23 SDs, and 5 PDs for 34 patients with a favorable median OS of 10.2 months[122]. A Phase 1b study of second-line pelareorep with pembrolizumab and chemotherapy reported 1 PR of 17.4 months and a DCR of 30% (3/10)[123]; an earlier study reported no benefit from pelareorep in combination with paclitaxel/carboplatin[124]. Trials combining MEK inhibitors with other targeted therapies, such as EGFR inhibitors[125] or PI3K-AKT pathway inhibitors[126-127], reported no PRs and frequent adverse events for patients with KRAS-mutated pancreatic cancer. Clinical trials combining various MEK inhibitors with gemcitabine reported no additional benefit compared to gemcitabine alone irrespective of KRAS mutation status[128-131], despite promising results in earlier trials of MEK inhibitor monotherapies[132-137]. In a Phase 1 study evaluating the MEK-pan-RAF dual inhibitor CH5126766, 6 patients harboring KRAS mutations experienced PRs, including 3 with non-small cell lung cancer (NCSLC), 1 with low-grade serous ovarian carcinoma (LGSOC), 1 with endometrial adenocarcinoma, and 1 with multiple myeloma[138]. Combination of CH5126766 with the FAK inhibitor defactinib elicited PR rates of 50% (4/8) for patients with KRAS-mutated LGSOC and 12% (2/17) for patients with KRAS-mutated NSCLC in a Phase 1 study[139-140] . Preclinical and clinical data suggest that KRAS mutations may predict clinical benefit from SHP2 inhibitors[141-142]. A Phase 1 study of RMC-4630 for relapsed/refractory solid tumors

reported a DCR of 58% (23/40) for patients with NSCLC and KRAS mutations and a DCR of 75% (12/16) for patients with NSCLC and KRAS G12C mutations[143]. Interim results from a Phase 1/2 study of RMC-4630 plus cobimetinib reported tumor reduction in 3 of 8 patients with KRAS-mutated colorectal cancer[144]. Preclinical studies suggest that KRAS activating mutations may confer sensitivity to SOS1 inhibitors such as BI-3406, MRTX0902, BI-1701963, and BAY-293 as single agents[145-150] or in combination with covalent KRAS G12C inhibitors[150] and MEK inhibitors[151-152].

FREQUENCY & PROGNOSIS
KRAS mutations have been observed in 91-95% of pancreatic ductal adenocarcinoma cases[92,153], with the majority of mutations found at codon 12[154-157]. KRAS mutations, particularly G12D, have been associated with decreased median survival time in patients with pancreatic ductal adenocarcinoma[155].

FINDING SUMMARY
KRAS encodes a member of the RAS family of small GTPases. Activating mutations in RAS genes can cause uncontrolled cell proliferation and tumor formation[114,158]. KRAS alterations affecting amino acids G12, G13, Q22, P34, A59, Q61, and A146, as well as mutations G10_A11insG, G10_A11insAG (also reported as G10_A11dup and G12_G13insAG), A18D, L19F, D33E, G60_A66dup/E62_A66dup, E62K, E63K, R68S, and K117N have been characterized as activating and oncogenic[114,159-181].

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

GENOMIC FINDINGS

ORDERED TEST # ORD-1600374-01

GENE
MTAP

ALTERATION
loss

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

MTAP inactivation produces specific metabolic vulnerabilities that may be sensitive to MAT2A[182-183] or PRMT5 inhibition[183-185]. A Phase 1 trial of MAT2A inhibitor AG-270 reported 1 PR and 2 SDs lasting longer than 6 months for patients with advanced solid tumors displaying MTAP loss[186]. Preclinical data suggest that MTAP loss sensitizes cells to S-adenosyl-L-methionine (SAM)-competitive PRMT5 inhibitors[187], dual PRMT1 and PRMT5 inhibitors[188-190], and PRMT5 inhibitors that selectively bind the PRMT5 when complexed with S-methyl-5'-thioadenosine (MTA), such as MRTX1719, TNG908, and AMG193[191]. In preclinical models, MTAP inactivation showed increased sensitivity to inhibitors of purine synthesis or purine analogs, especially upon addition of exogenous MTA[192-202]. A Phase 2 study of L-alanosine, an inhibitor of adenine synthesis, as a monotherapy for 65 patients with MTAP-deficient cancers reported no responses and SD for 24% (13/55) of patients[203]. Preclinical and limited clinical evidence suggest MTAP deficiency may confer sensitivity to pemetrexed[204].

FREQUENCY & PROGNOSIS

MTAP loss/homozygous deletion as well as loss of expression has been reported in a wide variety of solid tumors and hematologic cancers[205-206]; such events have been correlated with poor prognosis in a variety of cancer types, including hepatocellular carcinoma[207], gastrointestinal stromal tumors[208], mantle cell lymphoma (MCL)[209], melanoma[210-211], gastric cancer[212], myxofibrosarcoma[213], nasopharyngeal carcinoma[214], ovarian carcinoma[205] and non-small cell lung cancer[215]. MTAP loss was not prognostic in pediatric B-cell acute lymphocytic leukemia[216] or in astrocytoma[217]. However, MTAP has also been reported to be overexpressed in colorectal cancer (CRC) samples[218], and MTAP retention is thought to be important for prostate cancer growth due to continuous supply of SAM[219]. Germline SNPs in MTAP have been correlated with the development of cutaneous melanoma[220-221], esophageal cancer[222-223], osteosarcoma[224], and CRC[225].

FINDING SUMMARY

MTAP encodes S-methyl-5'-thioadenosine (MTA) phosphorylase, a tumor suppressor involved in polyamine metabolism and methionine synthesis, although its enzymatic function is dispensable for its tumor suppressor activity[226-227]. Decreased expression of MTAP leads to MTA accumulation within tumor cells and their microenvironment[207,228-229], thereby reducing intracellular arginine methylation[183-185] and altering cell signaling[229-230]. MTAP is located at 9p21, adjacent to CDKN2A and CDKN2B, with which it is frequently co-deleted in various cancers. Other alterations in MTAP are rare and have not been extensively characterized.

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

PAGE 6 of 23

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

GENOMIC FINDINGS

GENE
CDKN2A/B

ALTERATION
CDKN2B loss, CDKN2A loss

POTENTIAL TREATMENT STRATEGIES
— Targeted Therapies —

Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib[231-234]. Clinical data in mesothelioma, breast cancer, and uterine leiomyosarcoma indicate that CDKN2A loss may predict sensitivity to abemaciclib[235] and palbociclib treatment[236-237]. However, multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents[238-244]; it is not known whether CDK4/6 inhibitors would be beneficial in this case. The p15INK4b protein encoded by CDKN2B is known to inhibit CDK4, and although concomitant loss of CDKN2A and CDKN2B may predict sensitivity to CDK4/6 inhibitors, such as ribociclib, abemaciclib, and palbociclib[241-242,245-246], direct supporting data for CDKN2B alteration as a predictive biomarker for these therapies are limited[247-248]. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors[249-250], the clinical relevance of p14ARF as a predictive biomarker is not clear.

FREQUENCY & PROGNOSIS

CDKN2A/B loss has been reported in 36% of pancreatic ductal carcinomas[92]. CDKN2A loss has been reported in 25-100% of pancreatic ductal adenocarcinomas analyzed, with a portion of those due to gene deletion[155,251-253]. A study of multiple pancreatic cancer subtypes reported no CDKN2A mutations (0/6 samples) and loss of heterozygosity in only one of four samples of pancreatic acinar carcinomas, compared to mutation or loss of heterozygosity in 38% and 67% of pancreatic ductal carcinomas, respectively[254]. Promoter methylation affecting p16INK4a and p14ARF has been reported in 43% (16/37) and 20.6% (7/34), respectively, of pancreatic fluid specimens of patients with pancreatic carcinoma[255]. The loss or decrease of p16INK4a expression levels in pancreatic ductal adenocarcinoma has been reported in 32-80% of samples analyzed and one study reported concurrent loss of p16INK4a and p14ARF protein expression in 68% (19/28) of cases[251,256-257]. p16INK4a expression has been associated with improved OS in pancreatic adenocarcinoma patients in univariate and multivariate analysis[258]. Furthermore, CDKN2A alterations (deletion or mutation) in the presence of concomitant KRAS mutation may correlate with shorter survival in patients with pancreatic ductal adenocarcinoma[256].

FINDING SUMMARY

CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b[259-260]. Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth-suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6-cyclin-Rb pathway and loss of cell cycle control[261-262]. The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition[263-264]. One or more alterations observed here are predicted to result in p16INK4a loss of function[265-286]. One or more alterations seen here are predicted to result in p14ARF loss of function[269,286-289]. CDKN2B alterations such as seen here are predicted to inactivate p15INK4b[290].

POTENTIAL GERMLINE IMPLICATIONS

Germline CDKN2A mutation is associated with melanoma-pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer[291]. Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma[292-293]. CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases[294-296]. CDKN2A alteration has also been implicated in familial melanoma-astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors[297-299]. In the appropriate clinical context, germline testing of CDKN2A is recommended.

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal adenocarcinoma

REPORT DATE
07 Apr 2023

GENOMIC FINDINGS

ORDERED TEST # ORD-1600374-01

GENE

TP53

ALTERATION
C275W

HGVS VARIANT
NM_000546.4: c.825T>G (p.C275W)

VARIANT CHROMOSOMAL POSITION
chr17:7577113

VARIANT ALLELE FREQUENCY (% VAF)
11.1%

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[300-303] or p53 gene therapy such as SGT53[304-308]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[309]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[310]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[311]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[312]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib

combined with paclitaxel[313]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[314]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[315]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[308]. Missense mutations leading to TP53 inactivation may be sensitive to therapies that reactivate mutated p53 such as eprenetapopt. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, eprenetapopt combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[316]. A Phase 1 trial of eprenetapopt with pembrolizumab for patients with solid tumors reported an ORR of 10% (3/29)[317].

FREQUENCY & PROGNOSIS

TP53 mutations have been reported in 33-75% of pancreatic carcinomas, with the majority occurring as missense mutations, while deletion of TP53 has been found in 66% of pancreatic ductal adenocarcinoma cases[153,318-320]. TP53 mutations are common in pancreatic ductal adenocarcinomas and are known to occur in the process of pancreatic carcinogenesis[321-322]. Additionally, aberrant expression of p53 has been found in 54-81% of pancreatic ductal adenocarcinoma cases[256,319,323-324]. Studies have found inconsistent results regarding the prognostic significance of p53 expression in pancreatic ductal adenocarcinoma, although one study correlated low levels of TP53 mRNA with poor patient prognosis[256,325-326].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[327]. Alterations such as seen here may disrupt TP53 function or expression[328-332].

POTENTIAL GERMLINE IMPLICATIONS

Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[333-335], including sarcomas[336-337]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[338] to 1:20,000[337]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[339]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[340-345]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[340-341]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[346]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[344,347-348]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531

PAGE 8 of 23

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

THERAPIES WITH CLINICAL BENEFIT	IN PATIENT'S TUMOR TYPE

Olaparib

Assay findings association

BRCA1
splice site 5332+1G>A

AREAS OF THERAPEUTIC USE

The PARP inhibitor olaparib is FDA approved to treat patients with epithelial ovarian, Fallopian tube, or primary peritoneal cancer, patients with deleterious or suspected deleterious gBRCA-mutated pancreatic adenocarcinoma or HER2-negative breast cancer, and patients with prostate cancer and mutations in homologous recombination repair genes. Olaparib is also approved in combination with bevacizumab to treat patients with ovarian, Fallopian tube, or primary peritoneal cancer with deleterious or suspected deleterious somatic or gBRCA mutation and/or genomic instability. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of extensive clinical evidence in ovarian cancer[57-61] as well as strong clinical evidence in multiple other cancer types[47-49,57,60,64,349] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to olaparib.

SUPPORTING DATA

The Phase 3 randomized, placebo-controlled POLO trial investigating maintenance olaparib for patients with platinum-sensitive, germline BRCA1/2-mutated metastatic pancreatic adenocarcinoma reported a significantly longer median PFS compared with placebo (7.4 vs. 3.8 months, HR=0.53)[64]. At 3-year follow-up, an OS of 34% was reported for patients treated with olaparib compared with 18% for patients receiving placebo; however, olaparib maintenance therapy did not impact median OS (19.0 vs. 19.2 months, HR=0.83) relative to placebo[350]. A Phase 2 trial of olaparib monotherapy for patients with germline BRCA1/2-mutated recurrent pancreatic cancer reported a response rate of 22%[47]. Parallel Phase 2 trials reported 2 PRs for patients with platinum-sensitive, DNA damage repair (DDR) deficient, germline BRCA mutation-negative pancreatic ductal adenocarcinoma; no responses were observed in platinum-refractory cases[351]. In a Phase 2 study of olaparib plus pembrolizumab for advanced solid tumors, patients with BRCA1 or BRCA2 mutations achieved an ORR of 29% (6/21), whereas patients with mutations in other homologous recombination repair genes achieved an ORR of 6.3% (2/32)[352].

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

THERAPIES WITH CLINICAL BENEFIT | IN OTHER TUMOR TYPE

Niraparib

Assay findings association

BRCA1
splice site 5332+1G>A

AREAS OF THERAPEUTIC USE

The PARP inhibitor niraparib is FDA approved to treat patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer, with or without homologous recombination deficiency (HRD)-positive status. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of clinical evidence in ovarian and breast cancers[51-52,353], loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to PARP inhibitors such as niraparib.

SUPPORTING DATA

In a Phase 1b/2 study, 6-month PFS for patients with advanced pancreatic cancer treated with niraparib plus ipilimumab in the maintenance setting was 60% whereas those treated with niraparib plus nivolumab was 21%[354]. Niraparib has primarily been evaluated in the context of ovarian cancer. In a Phase 3 study of patients with platinum-sensitive, recurrent ovarian cancer, niraparib significantly increased median PFS compared with placebo in patients with germline BRCA mutations (21 vs. 5.5 months) and in patients without germline BRCA mutations (9.3 vs. 3.9 months), as well as in a subgroup of the patients without germline BRCA mutations with homologous recombination-deficient tumors (12.9 vs. 3.8 months)[51]. In a Phase 1 study of niraparib treatment for patients with solid tumors, 40% (8/20) of patients with ovarian cancer and BRCA mutations and 50% (2/4) of patients with breast cancer and BRCA mutations experienced a PR, and 43% (9/21) of patients with castration-resistant prostate cancer and 100% (2/2) of patients with non-small cell lung cancer experienced SD[52]. A Phase 1 study of the combination of niraparib and bevacizumab for patients with platinum-sensitive, high-grade ovarian cancer reported a DCR of 91% (10/11), with a response rate of 45% (5/11)[355]. A Phase 2 study of niraparib reported 1 PR and 8 SDs, with 78% (7/9) of patients with BAP1-mutated cholangiocarcinoma, mesothelioma, uveal melanoma, or clear cell renal cell carcinoma (ccRCC) experiencing SD[356]. A case study reported a patient with BAP1-mutated pretreated ccRCC experienced a PR of 5 months on niraparib[357].

Rucaparib

Assay findings association

BRCA1
splice site 5332+1G>A

AREAS OF THERAPEUTIC USE

The PARP inhibitor rucaparib is FDA approved to treat patients with metastatic castration-resistant prostate cancer (mCRPC) and deleterious somatic or germline BRCA mutations. Rucaparib is also approved as a maintenance treatment of patients with recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical evidence in ovarian cancer[53-54,310], as well as clinical data in other cancer types[54,358-359], loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to rucaparib.

SUPPORTING DATA

In the RUCAPANC Phase 2 study, rucaparib elicited an ORR of 16% and a DCR of 32% for BRCA1/2-mutated advanced or metastatic pancreatic cancer, with 2 CRs (1 confirmed, 1 unconfirmed) and 2 PRs out of 19 treated patients[360]. As maintenance therapy for BRCA1/2- or PALB2-mutated platinum-sensitive pancreatic cancer, rucaparib enabled a 6-month PFS rate of 60%, median PFS and OS of 13.1 and 23.5 months, and ORR of 41% (3/36 CRs, 2 ongoing for >1 year) in a Phase 2 study; 4 patients remained progression-free during >2 years of follow up[361-362]. In this trial, ORRs for patients with germline or somatic BRCA2 alterations were 41% (11/27) and 50% (1/2), respectively, and 50% (3/6) for those with germline PALB2 alterations; however, no objective responses were observed for any of 7 patients with germline BRCA1 alterations[361].

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

THERAPIES WITH CLINICAL BENEFIT | IN OTHER TUMOR TYPE

Talazoparib

Assay findings association

BRCA1
splice site 5332+1G>A

AREAS OF THERAPEUTIC USE

The PARP inhibitor talazoparib is FDA approved to treat HER2-negative locally advanced or metastatic breast cancer with deleterious or suspected deleterious germline BRCA mutations. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical data in breast cancer[363-365] and additional clinical evidence in ovarian, pancreatic, and prostate cancer[366-369] , loss or inactivation of either BRCA1 or BRCA2 may confer sensitivity to talazoparib.

SUPPORTING DATA

A Phase 1 study of talazoparib reported PRs for 20% (2/10) of patients with pancreatic cancer, 1 with a BRCA2 mutation and 1 with a PALB2 mutation[367]. Talazoparib has been studied primarily in the context of BRCA-mutated, HER2-negative breast cancer, where patients achieved significantly longer median PFS (8.6 vs. 5.6 months, HR=0.54), a higher ORR (62.6% vs. 27.2%), and improved quality of life on talazoparib compared with standard chemotherapy in a Phase 3 study[364-365] . In a Phase 2 study of talazoparib for BRCA1/2-wildtype patients with homologous recombination pathway alterations, the best outcome in non-breast tumors was SD ≥ 6 months for 2/7 patients who had colon cancer with germline ATM alteration or testicular cancer with germline CHEK2 and somatic ATM alteration[370]. Clinical activity of single-agent talazoparib has been observed in numerous other solid tumors, including responses in BRCA-mutated ovarian, pancreatic, prostate, and ampulla of Vater cancers; PALB2-mutated pancreatic and bladder cancers; ATM-mutated cholangiocarcinoma; and small cell lung cancer[366-368,371] .

NOTE Genomic alterations detected may be associated with activity of certain FDA approved drugs, however, the agents listed in this report may have varied evidence in the patient's tumor type.

FOUNDATION**ONE**®**CDx**

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

CLINICAL TRIALS

NOTE Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. Or, visit https://www.foundationmedicine.com/genomic-testing#support-services.

GENE
BRCA1

RATIONALE
BRCA1 loss or inactivating alterations may predict sensitivity to PARP inhibitors or ATR inhibitors.

ALTERATION
splice site 5332+1G>A

NCT03239015	**PHASE 2**
Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event	**TARGETS** EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6

LOCATIONS: Shanghai (China)

NCT04425876	**PHASE 1**
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer	**TARGETS** PARP

LOCATIONS: Shanghai (China)

NCT04123366	**PHASE 2**
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)	**TARGETS** PARP, PD-1

LOCATIONS: Fukuoka (Japan), Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Okayama (Japan), Nagoya (Japan), Tokyo (Japan), Kashiwa (Japan), Sapporo (Japan), Nedlands (Australia), Southport (Australia)

NCT03742895	**PHASE 2**
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)	**TARGETS** PARP

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Darlinghurst (Australia), Saint Petersburg (Russian Federation), Adana (Turkey), Jerusalem (Israel), Konya (Turkey), Ramat Gan (Israel), Istanbul (Turkey), Antalya (Turkey)

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

CLINICAL TRIALS

NCT02264678
PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), London (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom)

NCT05417594
PHASE 1/2

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

TARGETS
PARP

LOCATIONS: Seoul (Korea, Republic of), Melbourne (Australia), Stockholm (Sweden), Barcelona (Spain), Sant Cugat del Valles (Spain), Pozuelo de Alarcon (Spain), A Coruña (Spain), Sevilla (Spain), Texas

---

NCT05514132
PHASE 1

A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours

TARGETS
PD-L1, ATR

LOCATIONS: Beijing (China), Shandong (China)

NCT03188965
PHASE 1

First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

TARGETS
ATR

LOCATIONS: Kashiwa (Japan), Singapore (Singapore), Bellinzona (Switzerland)

NCT05035745
PHASE 1/2

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

TARGETS
XPO1, PARP

LOCATIONS: Singapore (Singapore)

NCT03772561
PHASE 1

Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies

TARGETS
PARP, AKTs, PD-L1

LOCATIONS: Singapore (Singapore)

Disclaimer: Foundation Medicine Inc. only provides PDF report as an official issuance of the test result. Any other transformed format is not an "official / formal solution" and not guarantee the accuracy of this conversion. It is suggested the hospital to verify the outputs and validate the suitability of use.

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

CLINICAL TRIALS

ORDERED TEST #   ORD-1600374-01

GENE
KRAS

ALTERATION
Q61H

RATIONALE
Multiple clinical studies have reported lack of efficacy of MEK inhibitors as monotherapy for treatment of KRAS-mutant pancreatic cancer. Emerging data suggest patients with KRAS-mutant pancreatic cancer may be sensitive to combination MEK/autophagy inhibitors. Limited clinical and preclinical studies indicate KRAS mutations may predict sensitivity to MEK-pan-RAF dual inhibitors. Preclinical evidence suggests that KRAS activating mutations may predict sensitivity to SOS1 inhibitors.

NCT04892017 — PHASE 1/2

A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.

TARGETS
ULK1, ULK2, MEK

LOCATIONS: Massachusetts, New York, Texas, Pennsylvania

NCT04132505 — PHASE 1

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Texas

NCT03825289 — PHASE 1

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer

TARGETS
MEK

LOCATIONS: Utah

FOUNDATIONONE®**CDx**

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

CLINICAL TRIALS

ORDERED TEST # ORD-1600374-01

GENE
MTAP

ALTERATION
loss

RATIONALE
MTAP loss may predict sensitivity to MAT2A inhibitors, or to inhibitors that target PRMT5 when in complex with MTA.

NCT05094336

PHASE 1/2

AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

TARGETS
PRMT5-MTA

LOCATIONS: Tainan (Taiwan), Shatin, New Territories (Hong Kong), Hong Kong (Hong Kong), Nagoya-shi (Japan), Chuo-ku (Japan), Kashiwa-shi (Japan), Camperdown (Australia), Halle (Saale) (Germany), Graz (Austria), Salzburg (Austria)

NCT05245500

PHASE 1/2

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

TARGETS
PRMT5-MTA

LOCATIONS: Colorado, Arizona, Minnesota, Massachusetts, New York, Tennessee, Texas, Florida

NCT05275478

PHASE 1/2

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

TARGETS
PRMT5-MTA

LOCATIONS: Lyon (France), Villejuif (France), Missouri, Massachusetts, Tennessee, Texas, Virginia

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

APPENDIX   Variants of Unknown Significance

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

ATRX
NM_000489.3: c.4858A>C
(p.S1620R)
chrX:76889152

CHEK2
NM_007194.3: c.542G>A
(p.R181H)
chr22:29121015

CYP17A1
NM_000102.3: c.764G>A
(p.R255Q)
chr10:104592955

EPHA3
NM_005233.4: c.2536C>A
(p.P846T)
chr3:89499366

FOXL2
NM_023067.3: c.464C>T
(p.P155L)
chr3:138665101

KDM5A
NM_001042603.1:
c.4664_4665delinsCT
(p.L1555P)
chr12:402126-402127

MET
NM_000245.2: c.65G>T
(p.S22I)
chr7:116339203

MST1R
NM_002447.2: c.461C>A
(p.A154D)
chr3:49940582

NKX2-1
NM_003317.3: c.964G>A
(p.G322S)
chr14:36986635

PIK3C2G
NM_004570.4:
c.3299_3306dup
(p.Y1103Vfs*15)
chr12:18691183

TSC1
NM_000368.4: c.1960C>G
(p.Q654E)
chr9:135781005

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

APPENDIX   Genes Assayed in FoundationOne®CDx

FoundationOne CDx is designed to include genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis based on current knowledge. The current assay interrogates 324 genes as well as introns of 36 genes involved in rearrangements. The assay will be updated periodically to reflect new knowledge about cancer biology.

DNA GENE LIST: ENTIRE CODING SEQUENCE FOR THE DETECTION OF BASE SUBSTITUTIONS, INSERTION/DELETIONS, AND COPY NUMBER ALTERATIONS

ABL1	ACVR1B	AKT1	AKT2	AKT3	ALK	ALOX12B	AMER1 (FAM123B or WTX)
APC	AR	ARAF	ARFRP1	ARID1A	ASXL1	ATM	ATR	ATRX
AURKA	AURKB	AXIN1	AXL	BAP1	BARD1	BCL2	BCL2L1	BCL2L2
BCL6	BCOR	BCORL1	BRAF	BRCA1	BRCA2	BRD4	BRIP1	BTG1
BTG2	BTK	CALR	CARD11	CASP8	CBFB	CBL	CCND1	CCND2
CCND3	CCNE1	CD22	CD274 (PD-L1)	CD70	CD79A	CD79B	CDC73	CDH1
CDK12	CDK4	CDK6	CDK8	CDKN1A	CDKN1B	CDKN2A	CDKN2B	CDKN2C
CEBPA	CHEK1	CHEK2	CIC	CREBBP	CRKL	CSF1R	CSF3R	CTCF
CTNNA1	CTNNB1	CUL3	CUL4A	CXCR4	CYP17A1	DAXX	DDR1	DDR2
DIS3	DNMT3A	DOT1L	EED	EGFR	EMSY (C11orf30)	EP300	EPHA3	EPHB1
EPHB4	ERBB2	ERBB3	ERBB4	ERCC4	ERG	ERRFI1	ESR1	EZH2
FANCA	FANCC	FANCG	FANCL	FAS	FBXW7	FGF10	FGF12	FGF14
FGF19	FGF23	FGF3	FGF4	FGF6	FGFR1	FGFR2	FGFR3	FGFR4
FH	FLCN	FLT1	FLT3	FOXL2	FUBP1	GABRA6	GATA3	GATA4
GATA6	GID4 (C17orf39)	GNA11	GNA13	GNAQ	GNAS	GRM3	GSK3B	H3-3A (H3F3A)
HDAC1	HGF	HNF1A	HRAS	HSD3B1	ID3	IDH1	IDH2	IGF1R
IKBKE	IKZF1	INPP4B	IRF2	IRF4	IRS2	JAK1	JAK2	JAK3
JUN	KDM5A	KDM5C	KDM6A	KDR	KEAP1	KEL	KIT	KLHL6
KMT2A (MLL)	KMT2D (MLL2)	KRAS	LTK	LYN	MAF	MAP2K1 (MEK1)	MAP2K2 (MEK2)	MAP2K4
MAP3K1	MAP3K13	MAPK1	MCL1	MDM2	MDM4	MED12	MEF2B	MEN1
MERTK	MET	MITF	MKNK1	MLH1	MPL	MRE11 (MRE11A)	MSH2	MSH3
MSH6	MST1R	MTAP	MTOR	MUTYH	MYC	MYCL (MYCL1)	MYCN	MYD88
NBN	NF1	NF2	NFE2L2	NFKBIA	NKX2-1	NOTCH1	NOTCH2	NOTCH3
NPM1	NRAS	NSD2 (WHSC1 or MMSET)		NSD3 (WHSC1L1)	NT5C2	NTRK1	NTRK2	NTRK3
P2RY8	PALB2	PARP1	PARP2	PARP3	PAX5	PBRM1	PDCD1 (PD-1)	PDCD1LG2 (PD-L2)
PDGFRA	PDGFRB	PDK1	PIK3C2B	PIK3C2G	PIK3CA	PIK3CB	PIK3R1	PIM1
PMS2	POLD1	POLE	PPARG	PPP2R1A	PPP2R2A	PRDM1	PRKAR1A	PRKCI
PRKN (PARK2)	PTCH1	PTEN	PTPN11	PTPRO	QKI	RAC1	RAD21	RAD51
RAD51B	RAD51C	RAD51D	RAD52	RAD54L	RAF1	RARA	RB1	RBM10
REL	RET	RICTOR	RNF43	ROS1	RPTOR	SDHA	SDHB	SDHC
SDHD	SETD2	SF3B1	SGK1	SMAD2	SMAD4	SMARCA4	SMARCB1	SMO
SNCAIP	SOCS1	SOX2	SOX9	SPEN	SPOP	SRC	STAG2	STAT3
STK11	SUFU	SYK	TBX3	TEK	TENT5C (FAM46C)		TET2	TGFBR2
TIPARP	TNFAIP3	TNFRSF14	TP53	TSC1	TSC2	TYRO3	U2AF1	VEGFA
VHL	WT1	XPO1	XRCC2	ZNF217	ZNF703			

DNA GENE LIST: FOR THE DETECTION OF SELECT REARRANGEMENTS

ALK	BCL2	BCR	BRAF	BRCA1	BRCA2	CD74	EGFR	ETV4
ETV5	ETV6	EWSR1	EZR	FGFR1	FGFR2	FGFR3	KIT	KMT2A (MLL)
MSH2	MYB	MYC	NOTCH2	NTRK1	NTRK2	NUTM1	PDGFRA	RAF1
RARA	RET	ROS1	RSPO2	SDC4	SLC34A2	TERC*	TERT**	TMPRSS2

*TERC is an NCRNA

**Promoter region of TERT is interrogated

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Homologous Recombination status

Loss of Heterozygosity (LOH) score

Microsatellite (MS) status

Tumor Mutational Burden (TMB)

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

FoundationOne CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a,

Cipalstraat 3, 2440 Geel, Belgium. CE

ABOUT FOUNDATIONONE CDX

FoundationOne CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details: www.rochefoundationmedicine.com/f1cdxtech.

INTENDED USE

FoundationOne®CDx (F1CDx) is a next generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI), tumor mutational burden (TMB), and for selected forms of ovarian cancer, loss of heterozygosity (LOH) score, using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with therapies in accordance with approved therapeutic product labeling. Additionally, F1CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms.

TEST PRINCIPLE

FoundationOne CDx will be performed exclusively as a laboratory service using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor samples. The proposed assay will employ a single DNA extraction method from routine FFPE biopsy or surgical resection specimens, 50-1000 ng of which will undergo whole-genome shotgun library construction and hybridization-based capture of all coding exons from 309 cancer-related genes, one promoter region, one non-coding (ncRNA), and select intronic regions from 34 commonly rearranged genes, 21 of which also include the coding exons. The assay therefore includes

detection of alterations in a total of 324 genes.

Using an Illumina® HiSeq platform, hybrid capture–selected libraries will be sequenced to high uniform depth (targeting >500X median coverage with >99% of exons at coverage >100X). Sequence data will be processed using a customized analysis pipeline designed to accurately detect all classes of genomic alterations, including base substitutions, indels, focal copy number amplifications, homozygous gene deletions, and selected genomic rearrangements (e.g.,gene fusions). Additionally, genomic signatures including loss of heterozygosity (LOH), microsatellite instability (MSI) and tumor mutational burden (TMB) will be reported.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. The F1CDx report may be used as an aid to inform molecular eligibility for clinical trials. Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

Diagnostic Significance

FoundationOne CDx identifies alterations to select cancer-associated genes or portions of genes (biomarkers). In some cases, the Report also highlights selected negative test results regarding biomarkers of clinical significance.

Qualified Alteration Calls (Equivocal and Subclonal)

An alteration denoted as "amplification – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence that the copy number of a gene exceeds the threshold for identifying copy number amplification. The threshold used in FoundationOne CDx for identifying a copy number amplification is four (4) for *ERBB2* and six (6) for all other genes. Conversely, an alteration denoted as "loss – equivocal" implies that the FoundationOne CDx assay data provide some, but not unambiguous, evidence for homozygous deletion of the gene in question. An alteration denoted as "subclonal" is one that the FoundationOne CDx analytical

methodology has identified as being present in <10% of the assayed tumor DNA.

Ranking of Therapies and Clinical Trials
Ranking of Therapies in Summary Table
Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials
Pediatric trial qualification → Geographical proximity → Later trial phase.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Limitations

1. In the fraction-based MSI algorithm, a tumor specimen will be categorized as MSI-H, MSS, or MS-Equivocal according to the fraction of microsatellite loci determined to be altered or unstable (i.e., the fraction unstable loci score). In the F1CDx assay, MSI is evaluated based on a genome-wide analysis across >2000 microsatellite loci. For a given microsatellite locus, non-somatic alleles are discarded, and the microsatellite is categorized as unstable if remaining alleles differ from the reference genome. The final fraction unstable loci score is calculated as the number of unstable microsatellite loci divided by the number of evaluable microsatellite loci. The MSI-H and MSS cut-off thresholds were determined by

FOUNDATION**ONE**®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

ORDERED TEST # ORD-1600374-01

APPENDIX | About FoundationOne®CDx

analytical concordance to a PCR comparator assay using a pan-tumor FFPE tissue sample set. Patients with results categorized as "MS-Stable" with median exon coverage <300X, "MS-Equivocal," or "Cannot Be Determined" should receive confirmatory testing using a validated orthogonal (alternative) method.

2. TMB by F1CDx is determined by counting all synonymous and non-synonymous variants present at 5% allele frequency or greater (after filtering) and the total number is reported as mutations per megabase (mut/Mb) unit. Observed TMB is dependent on characteristics of the specific tumor focus tested for a patient (e.g., primary vs. metastatic, tumor content) and the testing platform used for the detection; therefore, observed TMB results may vary between different specimens for the same patient and between detection methodologies employed on the same sample. The TMB calculation may differ from TMB calculations used by other assays depending on variables such as the amount of genome interrogated, percentage of tumor, assay limit of detection (LoD), filtering of alterations included in the score, and the read depth and other bioinformatic test specifications. Refer to the SSED for a detailed description of these variables in FMI's TMB calculation https://www.accessdata.fda.gov/cdrh_docs/pdf17/P170019B.pdf. The clinical validity of TMB defined by this panel has been established for TMB as a qualitative output for a cut-off of 10 mutations per megabase but has not been established for TMB as a quantitative score.

3. Homologous Recombination status may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas (Coleman et al., 2017; 28916367). Samples with deleterious *BRCA1/2* alteration and/or Loss of Heterozygosity (LOH) score ≥ 16% will be reported as "HRD Positive" and samples with absence of these findings will be reported as "HRD Not Detected," agnostic of potential secondary *BRCA1/2* reversion alterations. Certain potentially deleterious missense or small in-frame deletions in *BRCA1/2* may not be classified as deleterious and, in the absence of an elevated LOH profile, samples with such mutations may be classified as "HRD Not Detected." A result of "HRD Not Detected" does not rule out the presence of a *BRCA1/2* alteration or an elevated LOH profile outside the assay performance characteristic limitations.

4. The LOH score is determined by analyzing SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm- and chromosome-wide LOH segments. Detection of LOH has been verified only for ovarian cancer patients, and the LOH score result may be reported for epithelial ovarian, peritoneal, or Fallopian tube carcinomas. The LOH score will be reported as "Cannot Be Determined" if the sample is not of sufficient quality to confidently determine LOH. Performance of the LOH classification has not been established for samples below 35% tumor content. There may be potential interference of ethanol with LOH detection. The interfering effects of xylene, hemoglobin, and triglycerides on the LOH score have not been demonstrated.

5. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. The test does not provide information about susceptibility.

6. Biopsy may pose a risk to the patient when archival tissue is not available for use with the assay. The patient's physician should determine whether the patient is a candidate for biopsy.

7. Reflex testing to an alternative FDA approved companion diagnostic should be performed for patients who have an *ERBB2* amplification result detected with copy number equal to 4 (baseline ploidy of tumor +2) for confirmatory testing. While this result is considered negative by FoundationOne®CDx (F1CDx), in a clinical concordance study with an FDA approved FISH test, 70% (7 out of 10 samples) were positive, and 30% (3 out of 10 samples) were negative by the FISH test with an average ratio of 2.3. The frequency of *ERBB2* copy number 4 in breast cancer is estimated to be approximately 2%. Multiple references listed in https://www.mycancergenome.org/content/disease/breast-cancer/ERBB2/238/ report the frequency of HER2 overexpression as 20% in breast cancer. Based on the F1CDx HER2 CDx concordance study, approximately 10% of HER2 amplified samples had copy number 4. Thus, total frequency is conservatively estimated to be approximately 2%.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANT ALLELE FREQUENCY

Variant Allele Frequency (VAF) represents the fraction of sequencing reads in which the variant is observed. This attribute is not taken into account for therapy inclusion, clinical trial matching, or interpretive content. Caution is recommended in interpreting VAF to indicate the potential germline or somatic origin of an alteration, recognizing that tumor fraction and tumor ploidy of samples may vary.

Precision of VAF for base substitutions and indels

BASE SUBSTITUTIONS	%CV*
Repeatability	5.11 - 10.40
Reproducibility	5.95 - 12.31
INDELS	**%CV***
Repeatability	6.29 - 10.00
Reproducibility	7.33 - 11.71

Interquartile Range = 1st Quartile to 3rd Quartile

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >10%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL,* and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's

	PATIENT	TUMOR TYPE	REPORT DATE
FOUNDATIONONE®CDx	Chou, Kung Po	Pancreas ductal adenocarcinoma	07 Apr 2023

ORDERED TEST # ORD-1600374-01

APPENDIX   About FoundationOne®CDx

tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, CBL, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This Report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne CDx.

TREATMENT DECISIONS ARE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking

into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this Test, or the information contained in this Report. Certain sample or variant characteristics may result in reduced sensitivity. FoundationOne CDx is performed using DNA derived from tumor, and as such germline events may not be reported.

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

REFERENCE SEQUENCE INFORMATION

Sequence data is mapped to the human genome, Genome Reference Consortium Human Build 37 (GRCh37), also known as hg19.

MR Suite Version (RG) 7.7.0

The median exon coverage for this sample is 760x

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

FOUNDATIONONE®CDx

APPENDIX | References

ORDERED TEST # ORD-1600374-01

1. Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179
2. Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250
3. Lal N, et al. Oncoimmunology (2015) pmid: 25949894
4. Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255
5. Ayers et al., 2016; ASCO-SITC Abstract P60
6. Hu ZI, et al. Clin. Cancer Res. (2018) pmid: 29367431
7. Campbell BB, et al. Cell (2017) pmid: 29056344
8. Pihlak R, et al. Cancers (Basel) (2018) pmid: 29329208
9. Salem ME, et al. Mol. Cancer Res. (2018) pmid: 29523759
10. Laghi L, et al. PLoS ONE (2012) pmid: 23029359
11. Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942
12. You JF, et al. Br. J. Cancer (2010) pmid: 21081928
13. Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249
14. Boland CR, et al. Cancer Res. (1998) pmid: 9823339
15. Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785
16. Boland CR, et al. Gastroenterology (2010) pmid: 20420947
17. Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254
18. Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386
19. Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947
20. Cristescu R, et al. Science (2018) pmid: 30309915
21. Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829
22. Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845
23. Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128
24. Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394
25. Rozeman EA, et al. Nat Med (2021) pmid: 33558721
26. Sharma P, et al. Cancer Cell (2020) pmid: 32916128
27. Marabelle A, et al. Lancet Oncol. (2020) pmid: 32919526
28. Ott PA, et al. J. Clin. Oncol. (2019) pmid: 30557521
29. Cristescu R, et al. J Immunother Cancer (2022) pmid: 35101941
30. Friedman CF, et al. Cancer Discov (2022) pmid: 34876409
31. Sturgill EG, et al. Oncologist (2022) pmid: 35274716
32. Schenker at al., 2022; AACR Abstract 7845
33. Legrand et al., 2018; ASCO Abstract 12000
34. Chalmers ZR, et al. Genome Med (2017) pmid: 28420421
35. Hu et al., 2017; ASCO Abstract e15791
36. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
37. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
38. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
39. Rizvi NA, et al. Science (2015) pmid: 25765070
40. Johnson BE, et al. Science (2014) pmid: 24336570
41. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
42. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
43. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
44. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
45. Nature (2012) pmid: 22810696
46. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
47. Kaufman B, et al. J. Clin. Oncol. (2015) pmid: 25366685
48. Mateo J, et al. N. Engl. J. Med. (2015) pmid: 26510020
49. Tutt A, et al. Lancet (2010) pmid: 20609467
50. Robson M, et al. N. Engl. J. Med. (2017) pmid: 28578601
51. Mirza MR, et al. N. Engl. J. Med. (2016) pmid: 27717299
52. Sandhu SK, et al. Lancet Oncol. (2013) pmid: 23810788
53. Swisher EM, et al. Lancet Oncol. (2017) pmid: 27908594
54. Drew Y, et al. Br. J. Cancer (2016) pmid: 27002934
55. Pujade-Lauraine E, et al. Lancet Oncol. (2017) pmid: 28754483
56. Ledermann JA, et al. Lancet Oncol. (2016) pmid: 27617661
57. Fong PC, et al. N. Engl. J. Med. (2009) pmid: 19553641
58. Audeh MW, et al. Lancet (2010) pmid: 20609468
59. Fong PC, et al. J. Clin. Oncol. (2010) pmid: 20406929
60. Gelmon KA, et al. Lancet Oncol. (2011) pmid: 21862407
61. Kaye SB, et al. J. Clin. Oncol. (2012) pmid: 22203755
62. Domchek SM, et al. Gynecol. Oncol. (2016) pmid: 26723501
63. Moore K, et al. N. Engl. J. Med. (2018) pmid: 30345884
64. Golan T, et al. N. Engl. J. Med. (2019) pmid: 31157963
65. Yap TA, et al. Cancer Discov (2021) pmid: 32988960
66. Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124
67. Saito YD, et al. Cancer Treat Res Commun (2018) pmid: 31299005
68. O'Reilly EM, et al. J. Clin. Oncol. (2020) pmid: 31976786
69. O'Carrigan et al., 2016; ASCO Abstract 2504
70. Yap et al., 2016; AACR-NCI-EORTC Abstract 1LBA
71. Pouliot GP, et al. PLoS ONE (2019) pmid: 31721781
72. Kim H, et al. Clin. Cancer Res. (2017) pmid: 27993965
73. Jin J, et al. Neoplasia (2018) pmid: 29605721
74. Westin et al., 2021; ASCO Abstract 5505
75. Do K, et al. J. Clin. Oncol. (2015) pmid: 25964244
76. Yap et al., 2022; AACR Abstract CT007
77. Cruz C, et al. J. Clin. Oncol. (2018) pmid: 30240327
78. Poveda A, et al. Ann. Oncol. (2017) pmid: 28368437
79. García MJ, et al. Mol. Cancer Ther. (2013) pmid: 23364677
80. Schöffski P, et al. Eur. J. Cancer (2011) pmid: 21376569
81. Italiano A, et al. Cancer (2011) pmid: 21287534
82. Laroche-Clary A, et al. Br. J. Cancer (2015) pmid: 25602962
83. Ghouadni A, et al. Breast (2017) pmid: 28467918
84. Monk BJ, et al. Ann. Oncol. (2015) pmid: 25722380
85. Monk BJ, et al. Gynecol. Oncol. (2020) pmid: 31924332
86. Yasui H, et al. J Chemother (2016) pmid: 27077926
87. Conroy T, et al. N Engl J Med (2011) pmid: 21561347
88. Fogelman D, et al. Cancer Chemother Pharmacol (2015) pmid: 26126726
89. Wattenberg MM, et al. Br J Cancer (2020) pmid: 31787751
90. Golan T, et al. Br J Cancer (2014) pmid: 25072261
91. Bailey P, et al. Nature (2016) pmid: 26909576
92. Witkiewicz AK, et al. Nat Commun (2015) pmid: 25855536
93. Beger C, et al. Clin. Cancer Res. (2004) pmid: 15173085
94. Lucas AL, et al. Clin. Cancer Res. (2013) pmid: 23658460
95. MedGenMed (2005) pmid: 16369438
96. Kim R, et al. JOP (2012) pmid: 22406596
97. Naderi A, et al. Int J Gastrointest Cancer (2002) pmid: 12622420
98. Stadler ZK, et al. Cancer (2012) pmid: 21598239
99. O'Donovan PJ, et al. Carcinogenesis (2010) pmid: 20400477
100. Nelson AC, et al. Radiat. Res. (2010) pmid: 20681793
101. Silver DP, et al. Cancer Discov (2012) pmid: 22843421
102. Ludwig T, et al. Genes Dev. (2001) pmid: 11358863
103. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
104. Miki Y, et al. Science (1994) pmid: 7545954
105. Wooster R, et al. Nature () pmid: 8524414
106. Ford D, et al. Lancet (1994) pmid: 7907678
107. Whittemore AS, et al. Am. J. Hum. Genet. (1997) pmid: 9042908
108. Claus EB, et al. Cancer (1996) pmid: 8635102
109. Struewing JP, et al. N. Engl. J. Med. (1997) pmid: 9145676
110. Oddoux C, et al. Nat. Genet. (1996) pmid: 8841192
111. King MC, et al. Science (2003) pmid: 14576434
112. Hall MJ, et al. Cancer (2009) pmid: 19241424
113. Nakano H, et al. Proc. Natl. Acad. Sci. U.S.A. (1984) pmid: 6320174
114. Pylayeva-Gupta Y, et al. Nat. Rev. Cancer (2011) pmid: 21993244
115. Yamaguchi T, et al. Int. J. Oncol. (2011) pmid: 21523318
116. Watanabe M, et al. Cancer Sci. (2013) pmid: 23438367
117. Gilmartin AG, et al. Clin. Cancer Res. (2011) pmid: 21245089
118. Yeh JJ, et al. Mol. Cancer Ther. (2009) pmid: 19372556
119. Zhu X, et al. Lancet Oncol (2022) pmid: 35240087
120. Kinsey CG, et al. Nat. Med. (2019) pmid: 30833748
121. Bryant KL, et al. Nat. Med. (2019) pmid: 30833752
122. Mahalingam D, et al. Cancers (Basel) (2018) pmid: 29799479
123. Mahalingam D, et al. Clin. Cancer Res. (2019) pmid: 31694832
124. Noonan AM, et al. Mol. Ther. (2016) pmid: 27039845
125. Ko AH, et al. Clin. Cancer Res. (2016) pmid: 26251290
126. Chung V, et al. JAMA Oncol (2017) pmid: 27978579
127. Bedard PL, et al. Clin. Cancer Res. (2015) pmid: 25500057
128. Van Laethem JL, et al. Target Oncol (2017) pmid: 27975152
129. Infante JR, et al. Eur. J. Cancer (2013) pmid: 23583440
130. Infante JR, et al. Eur. J. Cancer (2014) pmid: 24915778
131. Van Cutsem E, et al. Int. J. Cancer (2018) pmid: 29756206
132. Bodoky G, et al. Invest New Drugs (2012) pmid: 21594619
133. Rinehart J, et al. J. Clin. Oncol. (2004) pmid: 15483017
134. Lorusso PM, et al. J. Clin. Oncol. (2005) pmid: 16009947
135. Infante JR, et al. Lancet Oncol. (2012) pmid: 22805291
136. Weekes CD, et al. Clin. Cancer Res. (2013) pmid: 23434733
137. Garrido-Laguna I, et al. Oncoscience (2015) pmid: 25897431
138. Guo C, et al. Lancet Oncol (2020) pmid: 33128873
139. Krebs et al., 2021; AACR Abstract CT019
140. Shinde et al., 2020; AACR Abstract CT143
141. Lu H, et al. Mol Cancer Ther (2019) pmid: 31068384
142. Mainardi S, et al. Nat Med (2018) pmid: 29808006
143. Koczywas et al., 2021; AACR Abstract LB001
144. Bendell et al., 2020; EORTC-NCI-AACR Abstract 5
145. Hofmann MH, et al. Cancer Discov (2021) pmid: 32816843
146. He H, et al. J Med Chem (2022) pmid: 36173339
147. Zhang S, et al. J Med Chem (2022) pmid: 36384290
148. Liu M, et al. ACS Med Chem Lett (2023) pmid: 36793426
149. Ramharter J, et al. J Med Chem (2021) pmid: 33719426
150. Ketcham JM, et al. J Med Chem (2022) pmid: 35833726
151. Plangger A, et al. Discov Oncol (2022) pmid: 36048281
152. Ma Y, et al. Cancers (Basel) (2022) pmid: 36139627
153. Biankin AV, et al. Nature (2012) pmid: 23103869

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

APPENDIX   References

ORDERED TEST #   ORD-1600374-01

154. Feldmann G, et al. J Hepatobiliary Pancreat Surg (2007) pmid: 17520196
155. Rachakonda PS, et al. PLoS ONE (2013) pmid: 23565280
156. Hruban RH, et al. Am. J. Pathol. (1993) pmid: 8342602
157. Maitra A, et al. Best Pract Res Clin Gastroenterol (2006) pmid: 16549325
158. Kahn S, et al. Anticancer Res. () pmid: 3310850
159. Akagi K, et al. Biochem. Biophys. Res. Commun. (2007) pmid: 17150185
160. Bollag G, et al. J. Biol. Chem. (1996) pmid: 8955068
161. Buhrman G, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20194776
162. Sci. STKE (2004) pmid: 15367757
163. Edkins S, et al. Cancer Biol. Ther. (2006) pmid: 16969076
164. Feig LA, et al. Mol. Cell. Biol. (1988) pmid: 3043178
165. Gremer L, et al. Hum. Mutat. (2011) pmid: 20949621
166. Janakiraman M, et al. Cancer Res. (2010) pmid: 20570890
167. Kim E, et al. Cancer Discov (2016) pmid: 27147599
168. Lukman S, et al. PLoS Comput. Biol. (2010) pmid: 20838576
169. Naguib A, et al. J Mol Signal (2011) pmid: 21371307
170. Prior IA, et al. Cancer Res. (2012) pmid: 22589270
171. Privé GG, et al. Proc. Natl. Acad. Sci. U.S.A. (1992) pmid: 1565661
172. Scheffzek K, et al. Science (1997) pmid: 9219684
173. Scholl C, et al. Cell (2009) pmid: 19490892
174. Smith G, et al. Br. J. Cancer (2010) pmid: 20147967
175. Tyner JW, et al. Blood (2009) pmid: 19075190
176. Valencia A, et al. Biochemistry (1991) pmid: 2029511
177. White Y, et al. Nat Commun (2016) pmid: 26854029
178. Wiest JS, et al. Oncogene (1994) pmid: 8058307
179. Angeles AKJ, et al. Oncol Lett (2019) pmid: 31289513
180. Tong JH, et al. Cancer Biol. Ther. (2014) pmid: 24642870
181. Loree JM, et al. Clin Cancer Res (2021) pmid: 34117033
182. Kalev P, et al. Cancer Cell (2021) pmid: 33450196
183. Marjon K, et al. Cell Rep (2016) pmid: 27068473
184. Mavrakis KJ, et al. Science (2016) pmid: 26912361
185. Kryukov GV, et al. Science (2016) pmid: 26912360
186. Heist et al., 2019; AACR-NCI-EORTC Abstract B116
187. Guccione E, et al. Nat. Rev. Mol. Cell Biol. (2019) pmid: 31350521
188. Fedoriw A, et al. Cancer Cell (2019) pmid: 31257072
189. Srour N, et al. Cancer Cell (2019) pmid: 31287990
190. Gao G, et al. Nucleic Acids Res. (2019) pmid: 30916320
191. Smith CR, et al. J Med Chem (2022) pmid: 35041419
192. Hansen LJ, et al. Cancer Res. (2019) pmid: 31040154
193. Tang B, et al. Cancer Res. (2018) pmid: 29844120
194. Munshi PN, et al. Oncologist (2014) pmid: 24928612
195. de Oliveira SF, et al. PLoS ONE (2016) pmid: 26751376
196. Lubin M, et al. PLoS ONE (2009) pmid: 19478948
197. Tang B, et al. Cancer Biol. Ther. (2012) pmid: 22825330
198. Collins CC, et al. Mol. Cancer Ther. (2012) pmid: 22252602
199. Bertino JR, et al. Cancer Biol. Ther. (2011) pmid: 21301207
200. Coulthard SA, et al. Mol. Cancer Ther. (2011) pmid: 21282358
201. Miyazaki S, et al. Int. J. Oncol. (2007) pmid: 17912432
202. Efferth T, et al. Blood Cells Mol. Dis. () pmid: 11987241
203. Kindler HL, et al. Invest New Drugs (2009) pmid: 18618081
204. Alhalabi O, et al. Nat Commun (2022) pmid: 35379845
205. Wei R, et al. Sci Rep (2016) pmid: 27929028

206. Zhao M, et al. BMC Genomics (2016) pmid: 27556634
207. Kirovski G, et al. Am. J. Pathol. (2011) pmid: 21356366
208. Huang HY, et al. Clin. Cancer Res. (2009) pmid: 19887491
209. Marcé S, et al. Clin. Cancer Res. (2006) pmid: 16778103
210. Meyer S, et al. Exp. Dermatol. (2010) pmid: 20500769
211. Wild PJ, et al. Arch Dermatol (2006) pmid: 16618867
212. Kim J, et al. Genes Chromosomes Cancer (2011) pmid: 21412930
213. Li CF, et al. Oncotarget (2014) pmid: 25426549
214. He HL, et al. Medicine (Baltimore) (2015) pmid: 26656376
215. Su CY, et al. Eur J Surg Oncol (2014) pmid: 24969958
216. Mirebeau D, et al. Haematologica (2006) pmid: 16818274
217. Becker AP, et al. Pathobiology (2015) pmid: 26088413
218. Snezhkina AV, et al. Oxid Med Cell Longev (2016) pmid: 27433286
219. Bistulfi G, et al. Oncotarget (2016) pmid: 26910893
220. Antonopoulou K, et al. J. Invest. Dermatol. (2015) pmid: 25407435
221. Maccioni L, et al. BMC Cancer (2013) pmid: 23816148
222. Hyland PL, et al. Int J Epidemiol (2016) pmid: 26635288
223. Lin X, et al. Cancer Sci. (2017) pmid: 27960044
224. Zhi L, et al. J Cancer (2016) pmid: 27994653
225. Gu F, et al. Br. J. Cancer (2013) pmid: 23361049
226. Limm K, et al. PLoS ONE (2016) pmid: 27479139
227. Tang B, et al. G3 (Bethesda) (2014) pmid: 25387827
228. Limm K, et al. Eur. J. Cancer (2013) pmid: 23265702
229. Stevens AP, et al. J. Cell. Biochem. (2009) pmid: 19097084
230. Limm K, et al. Eur. J. Cancer (2014) pmid: 25087184
231. Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246
232. Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868
233. Cen L, et al. Neuro-oncology (2012) pmid: 22711607
234. Logan JE, et al. Anticancer Res. (2013) pmid: 23898052
235. Fennell DA, et al. Lancet Oncol (2022) pmid: 35157829
236. Elvin JA, et al. Oncologist (2017) pmid: 28283584
237. Gao J, et al. Curr Oncol (2015) pmid: 26715889
238. Gopalan et al., 2014; ASCO Abstract 8077
239. Peguero et al., 2016; ASCO Abstract 2528
240. Konecny et al., 2016; ASCO Abstract 5557
241. DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126
242. Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798
243. Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767
244. Johnson DB, et al. Oncologist (2014) pmid: 24797823
245. Flaherty KT, et al. Clin. Cancer Res. (2012) pmid: 22090362
246. Dickson MA, et al. J. Clin. Oncol. (2013) pmid: 23569312
247. Su D, et al. Nat Commun (2019) pmid: 31700061
248. Tramontana TF, et al. JCO Precis Oncol (2020) pmid: 32923894
249. Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101
250. Gamble LD, et al. Oncogene (2012) pmid: 21725357
251. Tsiambas E, et al. J BUON () pmid: 17600882
252. Bergmann F, et al. J. Clin. Pathol. (2006) pmid: 16497872
253. Attri J, et al. BMC Gastroenterol (2005) pmid: 15985168
254. Moore PS, et al. Br. J. Cancer (2001) pmid: 11161385
255. Klump B, et al. Br. J. Cancer (2003) pmid: 12610506
256. Oshima M, et al. Ann. Surg. (2013) pmid: 23470568

257. Geradts J, et al. Mod. Pathol. (2001) pmid: 11706079
258. Chang DT, et al. Cancer (2010) pmid: 20665497
259. Quelle DE, et al. Cell (1995) pmid: 8521522
260. Mutat. Res. (2005) pmid: 15878778
261. Gazzeri S, et al. Oncogene (1998) pmid: 9484839
262. Oncogene (1999) pmid: 10498883
263. Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746
264. Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699
265. Ruas M, et al. Oncogene (1999) pmid: 10498896
266. Jones R, et al. Cancer Res. (2007) pmid: 17909018
267. Haferkamp S, et al. Aging Cell (2008) pmid: 18843795
268. Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717
269. Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711
270. Gombart AF, et al. Leukemia (1997) pmid: 9324288
271. Yang R, et al. Cancer Res. (1995) pmid: 7780957
272. Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202
273. Greenblatt MS, et al. Oncogene (2003) pmid: 12606942
274. Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434
275. Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261
276. Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926
277. Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062
278. Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365
279. Koh J, et al. Nature (1995) pmid: 7777061
280. McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136
281. Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282
282. Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385
283. Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262
284. Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892
285. Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768
286. Rutter JL, et al. Oncogene (2003) pmid: 12853981
287. Itahana K, et al. Cancer Cell (2008) pmid: 18538737
288. Zhang Y, et al. Mol. Cell (1999) pmid: 10360174
289. Zhang Y, et al. Cell (1998) pmid: 9529249
290. Jafri M, et al. Cancer Discov (2015) pmid: 25873077
291. Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917
292. Adv Exp Med Biol (2010) pmid: 20687502
293. Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083
294. De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703
295. Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650
296. Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243
297. Kaufman DK, et al. Neurology (1993) pmid: 8414022
298. Bahuau M, et al. Cancer Res (1998) pmid: 9622062
299. Chan AK, et al. Clin Neuropathol () pmid: 28699883
300. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
301. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
302. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
303. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
304. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
305. Xu L, et al. Mol. Med. (2001) pmid: 11713371
306. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
307. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
308. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628

FOUNDATIONONE®CDx

PATIENT
Chou, Kung Po

TUMOR TYPE
Pancreas ductal
adenocarcinoma

REPORT DATE
07 Apr 2023

APPENDIX   References

ORDERED TEST #   ORD-1600374-01

309. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
310. Moore et al., 2019; ASCO Abstract 5513
311. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
312. Oza et al., 2015; ASCO Abstract 5506
313. Lee J, et al. Cancer Discov (2019) pmid: 31315834
314. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
315. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
316. Gourley et al., 2016; ASCO Abstract 5571
317. Park H, et al. ESMO Open (2022) pmid: 36084396
318. Morton JP, et al. Proc. Natl. Acad. Sci. U.S.A. (2010) pmid: 20018721
319. Scarpa A, et al. Am. J. Pathol. (1993) pmid: 8494051
320. Luo Y, et al. Pathol. Oncol. Res. (2013) pmid: 22782330
321. Iacobuzio-Donahue CA, et al. Clin. Cancer Res. (2012) pmid: 22896692
322. Macgregor-Das AM, et al. J Surg Oncol (2013) pmid: 22806689
323. Ottenhof NA, et al. Cell Oncol (Dordr) (2012) pmid: 22351431
324. Tsiambas E, et al. J BUON () pmid: 20414934
325. Ansari D, et al. Br J Surg (2011) pmid: 21644238
326. Grochola LF, et al. Pancreas (2011) pmid: 21404460
327. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
328. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
329. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
330. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
331. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
332. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
333. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
334. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
335. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
336. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
337. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
338. Lalloo F, et al. Lancet (2003) pmid: 12672316
339. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
340. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
341. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
342. Xie M, et al. Nat. Med. (2014) pmid: 25326804
343. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
344. Severson EA, et al. Blood (2018) pmid: 29678827
345. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
346. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
347. Chabon JJ, et al. Nature (2020) pmid: 32269342
348. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
349. Del Conte G, et al. Br. J. Cancer (2014) pmid: 25025963
350. Golan et al., 2021; ASCO Abstract 378
351. Golan et al., 2018; ASCO Abstract 297
352. Maio et al., 2021; AACR Abstract CT178
353. Konstantinopolous et al., 2018; ASCO Abstract 106
354. Reiss KA, et al. Lancet Oncol (2022) pmid: 35810751
355. Mirza et al., 2016; ASCO Abstract 5555
356. George et al., 2022; ASCO Abstract 3122
357. Lian BJ, et al. Front Oncol (2022) pmid: 35875073
358. Kristeleit et al., 2014; ASCO Abstract 2573
359. Domcheck et al., 2016; ASCO Abstract 4110
360. Shroff RT, et al. JCO Precis Oncol (2018) pmid: 30051098
361. Reiss KA, et al. J Clin Oncol (2021) pmid: 33970687
362. Binder et al., 2019; AACR Abstract CT234
363. Turner et al., 2017; ASCO Abstract 1007
364. Litton JK, et al. N. Engl. J. Med. (2018) pmid: 30110579
365. Ettl J, et al. Ann. Oncol. (2018) pmid: 30124753
366. Meehan et al., 2017; AACR Abstract 4687
367. de Bono J, et al. Cancer Discov (2017) pmid: 28242752
368. Lu E, et al. J Natl Compr Canc Netw (2018) pmid: 30099369
369. De Bono et al., 2020; ASCO Abstract 5566
370. Gruber et al., 2019; ASCO Abstract 3006
371. Piha-Paul et al., 2017; EORTC-NCI-AACR Abstract A096

Electronically signed by Erik Williams, M.D. | 07 April 2023
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. | www.rochefoundationmedicine.com

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX - PAGE 23 OF 23